In­di­a's TCG launch­es new CD­MO arm state­side to meet the call for 'Amer­i­can-made' pan­dem­ic drugs

Thanks to 57,000 square feet of re­al es­tate in New Jer­sey and Vir­ginia, a new CD­MO arm of In­dia’s TCG Life­sciences now has a US foot­print and will use it to fo­cus on ef­fi­cient and cheap pro­duc­tion of Covid-19 re­lat­ed med­i­cines and oth­er an­tivi­ral drugs.

Called TCG GreenChem, the new man­u­fac­tur­ing sub­sidiary will op­er­ate out of 3,000 square feet of lab space in Vir­ginia Com­mon­wealth Uni­ver­si­ty’s Biotech­nol­o­gy Re­search Park and 54,000 square feet of lab and of­fice space in Prince­ton’s South Cor­po­rate Cen­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER